Olivia Ziegler

Olivia Ziegler

Auto-generated profile, based on publicly available information

Olivia Ziegler

Department of Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJin Li
Jin Li
MCMun Chun Chan
Mun Chun Chan
YYYan Yu
Yan Yu
YBYihua Bei
Yihua Bei
PCPing Chen
Ping Chen
JXJunjie Xiao
Junjie Xiao
A number of microRNAs (miRNAs, miRs) have been shown to play a role in skeletal muscle atrophy, but their role is not completely understood. Here we show that miR-29b promotes skeletal muscle atrophy in response to different atrophic stimuli in cells and in mouse models. miR-29b promotes atrophy of myotubes differentiated from C2C12 or primary myoblasts, and conversely, its inhibition attenuates atrophy induced by dexamethasone (Dex), TNF-α and H2O2 treatment. Targeting of IGF-1 and PI3K(p85α) by miR-29b is required for induction of muscle atrophy. In vivo, miR-29b overexpression is sufficient to promote muscle atrophy while inhibition of miR-29b attenuates atrophy induced by denervation and immobilization. These data suggest that miR-29b contributes to multiple types of muscle atrophy via targeting of IGF-1 and PI3K(p85α), and that suppression of miR-29b may represent a therapeutic approach for muscle atrophy induced by different stimuli.

21 August 2017 in Obesity
Verified
Journal Article
Open access
PDF file
AJAngela Jones
Angela Jones
Kirsty DanielsonKirsty Danielson
Kirsty Danielson
MBMiles C. Benton
Miles C. Benton
OZOlivia Ziegler
Olivia Ziegler
RSRavi Shah
Ravi Shah
DMDonia Macartney‐Coxson
Donia Macartney‐Coxson
Objective: Extracellular microRNAs (miRNAs) represent functional biomarkers for obesity and related disorders; this study investigated plasma miRNAs in insulin resistance phenotypes in obesity.Methods: One hundred seventy‐five miRNAs were analyzed in females with obesity (insulin sensitivity, n = 11; insulin resistance, n = 19; type 2 diabetes, n = 15) and without obesity (n = 12). Correlations between miRNA level and clinical parameters and levels of 15 miRNAs in a murine obesity model were investigated.Results: One hundred six miRNAs were significantly (adjusted P ≤ 0.05) different between controls and at least one obesity phenotype, including miRNAs with the following attributes: previously reported roles in obesity and altered circulating levels (e.g., miR‐122, miR‐192); known roles in obesity but no reported changes in circulating levels (e.g., miR‐378a); and no current reported role in, or association with, obesity (e.g., miR‐28‐5p, miR‐374b, miR‐32). The miRNAs in the latter group were found to be associated with extracellular vesicles. Forty‐eight miRNAs showed significant correlations with clinical parameters; stepwise regression retained let‐7b, miR‐144‐5p, miR‐34a, and miR‐532‐5p in a model predictive of insulin resistance (R2 = 0.57, P = 7.5 × 10−8). Both miR‐378a and miR‐122 were perturbed in metabolically relevant tissues in a murine model of obesity.Conclusions: This study expands on the role of extracellular miRNAs in insulin‐resistant phenotypes of obesity and identifies candidate miRNAs not previously associated with obesity.

1 January 2018
Verified
Book Chapter
Closed access
PDF file
NSNoah Sadik
Noah Sadik
LCLilian Cruz
Lilian Cruz
AGAlessandra Gurtner
Alessandra Gurtner
RRRodosthenis S. Rodosthenous
Rodosthenis S. Rodosthenous
SDSophie Dusoswa
Sophie Dusoswa
Leonora BalajLeonora Balaj
Leonora Balaj

5 May 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
AYAshish Yeri
Ashish Yeri
ACAmanda Courtright
Amanda Courtright
Kirsty DanielsonKirsty Danielson
Kirsty Danielson
EHElizabeth Hutchins
Elizabeth Hutchins
EAEric Alsop
Eric Alsop
KKKendall Van Keuren-Jensen
Kendall Van Keuren-Jensen
Evolving interest in comprehensively profiling the full range of small RNAs present in small tissue biopsies and in circulating biofluids, and how the profile differs with disease, has launched small RNA sequencing (RNASeq) into more frequent use. However, known biases associated with small RNASeq, compounded by low RNA inputs, have been both a significant concern and a hurdle to widespread adoption. As RNASeq is becoming a viable choice for the discovery of small RNAs in low input samples and more labs are employing it, there should be benchmark datasets to test and evaluate the performance of new sequencing protocols and operators. In a recent publication from the National Institute of Standards and Technology, Pine et al., 2018, the investigators used a commercially available set of three tissues and tested performance across labs and platforms. In this paper, we further tested the performance of low RNA input in three commonly used and commercially available RNASeq library preparation kits; NEB Next, NEXTFlex, and TruSeq small RNA library preparation. We evaluated the performance of the kits at two different sites, using three different tissues (brain, liver, and placenta) with high (1 μg) and low RNA (10 ng) input from tissue samples, or 5.0, 3.0, 2.0, 1.0, 0.5, and 0.2 ml starting volumes of plasma. As there has been a lack of robust validation platforms for differentially expressed miRNAs, we also compared low input RNASeq data with their expression profiles on three different platforms (Abcam Fireplex, HTG EdgeSeq, and Qiagen miRNome). The concordance of RNASeq results on these three platforms was dependent on the RNA expression level; the higher the expression, the better the reproducibility. The results provide an extensive analysis of small RNASeq kit performance using low RNA input, and replication of these data on three downstream technologies.

1 December 2017 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
RSRavi Shah
Ravi Shah
AYAshish Yeri
Ashish Yeri
ADAvash Das
Avash Das
ACAmanda Courtright-Lim
Amanda Courtright-Lim
OZOlivia Ziegler
Olivia Ziegler
SDSaumya Das
Saumya Das
Exercise improves cardiometabolic and vascular function, although the mechanisms remain unclear. Our objective was to demonstrate the diversity of circulating extracellular RNA (ex-RNA) release during acute exercise in humans and its relevance to exercise-mediated benefits on vascular inflammation. We performed plasma small RNA sequencing in 26 individuals undergoing symptom-limited maximal treadmill exercise, with replication of our top candidate miRNA in a separate cohort of 59 individuals undergoing bicycle ergometry. We found changes in miRNAs and other ex-RNAs with exercise (e.g., Y RNAs and tRNAs) implicated in cardiovascular disease. In two independent cohorts of acute maximal exercise, we identified miR-181b-5p as a key ex-RNA increased in plasma after exercise, with validation in a separate cohort. In a mouse model of acute exercise, we found significant increases in miR-181b-5p expression in skeletal muscle after acute exercise in young (but not older) mice. Previous work revealed a strong role for miR-181b-5p in vascular inflammation in obesity, insulin resistance, sepsis, and cardiovascular disease. We conclude that circulating ex-RNAs were altered in plasma after acute exercise target pathways involved in inflammation, including miR-181b-5p. Further investigation into the role of known (e.g., miRNA) and novel (e.g., Y RNAs) RNAs is warranted to uncover new mechanisms of vascular inflammation on exercise-mediated benefits on health. NEW & NOTEWORTHY How exercise provides benefits to cardiometabolic health remains unclear. We performed RNA sequencing in plasma during exercise to identify the landscape of small noncoding circulating transcriptional changes. Our results suggest a link between inflammation and exercise, providing rich data on circulating noncoding RNAs for future studies by the scientific community.

1 February 2018 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
RSRavi Shah
Ravi Shah
OZOlivia Ziegler
Olivia Ziegler
AYAshish Yeri
Ashish Yeri
XLXiaojun Liu
Xiaojun Liu
VMVenkatesh Murthy
Venkatesh Murthy
SDSaumya Das
Saumya Das
Background: Plasma extracellular RNAs have recently garnered interest as biomarkers in heart failure (HF). Most studies in HF focus on single extracellular RNAs related to phenotypes and outcomes, and few describe their functional roles. We hypothesized that clusters of plasma microRNAs (miRNAs) associated with left ventricular (LV) remodeling in human HF would identify novel subsets of genes involved in HF in animal models. Methods and Results: We prospectively measured circulating miRNAs in 64 patients with systolic HF (mean age, 64.8 years; 91% men; median LV ejection fraction, 26%) with serial echocardiography (10 months apart) during medical therapy. We defined LV reverse remodeling as a 15% reduction in LV end-systolic volume index. Using principal components analysis, we identified a component associated with LV reverse remodeling (odds ratio=3.99; P =0.01) that provided risk discrimination for LV reverse remodeling superior to a clinical model (C statistic, 0.58 for a clinical model versus 0.71 for RNA-based model). Using network bioinformatics, we uncovered genes not previously widely described in HF regulated simultaneously by >2 miRNAs. We observed increased myocardial expression of these miRNAs during HF development in animals, with downregulation of target gene expression, suggesting coordinate miRNA–mRNA regulation. Target mRNAs were involved in autophagy, metabolism, and inflammation. Conclusions: Plasma miRNAs associated with LV reverse remodeling in humans are dysregulated in animal HF and target clusters of genes involved in mechanisms implicated in HF. A translational approach integrating human HF, bioinformatics, and model systems may uncover novel pathways involved in HF. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00351390